Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity

Lena Quambusch, Ina Landel, Laura Depta, Jörn Weisner, Niklas Uhlenbrock, Matthias P. Müller, Franziska Glanemann, Kristina Althoff, Jens T. Siveke, Daniel Rauh

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly selective bioactive small molecules. Herein, we present a structure-guided approach for the design of structurally diverse and pharmacologically beneficial covalent-allosteric modifiers, which enabled an investigation of the isoform-specific preferences and the important residues within the allosteric site of the different isoforms. The biochemical, cellular, and structural evaluations revealed interactions responsible for the selective binding profiles. The isoform-selective covalent-allosteric Akt inhibitors that emerged from this approach showed a conclusive structure–activity relationship and broke ground in the development of selective probes to delineate the isoform-specific functions of Akt kinases.

Original languageEnglish
Pages (from-to)18823-18829
Number of pages7
JournalAngewandte Chemie International Edition in English
Volume58
Issue number52
DOIs
StatePublished - 19 Dec 2019
Externally publishedYes

Keywords

  • Akt isoforms
  • allosteric sites
  • cancer
  • covalent inhibitors
  • isoform selectivity

Fingerprint

Dive into the research topics of 'Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity'. Together they form a unique fingerprint.

Cite this